Monitor for any subsequent amendment converting this 13G to a 13D, which would signal activist intent. Millennium's multi-strategy platform could eventually push for operational or strategic changes if the stock underperforms.
Price Chart
Executive Summary
Millennium Management LLC disclosed a 5.4% passive stake in Indivior Pharmaceuticals via a Schedule 13G filed September 30, 2026, representing 6,343,651 common shares. This is a new position for Millennium, adding a notable hedge fund holder alongside existing passive filers Vanguard, Fuller & Thaler, and Madison Avenue Partners. The filing is neutral as a passive stake, but Millennium's presence adds a layer of monitoring for potential future activism.
Key Financial Metrics
Key Facts
- Millennium Management LLC disclosed beneficial ownership of 6,343,651 shares of Indivior Pharmaceuticals common stock.
- The stake represents 5.4% of shares outstanding as of September 23, 2026.
- Filing is under Rule 13d-1(c) — passive investment, no intent to influence control.
- Joint filers include Millennium Group Management LLC and Israel A. Englander.
- This is a new 13G filing (not an amendment) for Millennium; prior 13G filers include Vanguard, Fuller & Thaler, and Madison Avenue Partners.
Financial Impact
5.4% passive stake valued at approximately $6.3 million based on share count and typical price range (no specific price per share disclosed in filing).
Risk Factors
- Millennium could increase or decrease position without further disclosure until crossing 5% threshold again.
- Passive filing does not preclude future activist engagement; any shift to 13D would be a material event.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001104659-26-112446 |
| Document: 0001104659-26-112446-index-headers.html | 0001104659-26-112446 |
| Document: 0001104659-26-112446-index.html | 0001104659-26-112446 |
| Document: 0001104659-26-112446.txt | 0001104659-26-112446 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Institutional Cluster | $34.79 | awaiting T+60 | — | $34.56 (−0.66%) |
Oct 19, 2026 7d ago | Press Release | $33.87 | awaiting T+60 | — | $34.56 (+2.04%) |
Oct 6, 2026 20d ago | 425 | $35.90 | awaiting T+60 | — | $34.56 (−3.73%) |
Oct 6, 2026 20d ago | 8-K | $35.90 | awaiting T+60 | — | $34.56 (−3.73%) |
Sep 30, 2026 25d ago | SC 13G | $35.38 | awaiting T+60 | — | $34.56 (−2.32%) |
Sep 17, 2026 5w ago | 425 | $35.69 | awaiting T+60 | — | $34.56 (−3.17%) |
Sep 17, 2026 5w ago | 8-K | $35.69 | awaiting T+60 | — | $34.56 (−3.17%) |
Sep 17, 2026 5w ago | Press Release | $35.69 | awaiting T+60 | — | $34.56 (−3.17%) |
Sep 14, 2026 6w ago | EFFECT | $34.47 | awaiting T+60 | — | $34.56 (+0.26%) |
Aug 28, 2026 8w ago | S-4 | $34.93 | awaiting T+60 | — | $34.56 (−1.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers